ArticleBMC complementary medicine and therapies2026
An integrated network pharmacology and proteomics approach reveals the anti-fibrotic effect of Fushen Granule on peritoneal fibrosis.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundFushen Granule (FSG), a Chinese medicine formular, was used clinically to improve the efficiency of dialysis in end-stage renal disease patients receiving peritoneal dialysis treatment. However, the mechanisms of its antifibrotic effect on peritoneal fibrosis (PF) have not yet been studied. In this study, we aimed to identify the potential mechanism of FSG in intervening in PF.
methodsNetwork pharmacology analysis and molecular docking were used to predict the related ingredients and potential targets of FSG in treating PF. TGF-β1 induced MeT5A cells were used for in vitro verification. Label-free proteomics analysis was performed to detect the differentially expressed proteins in TGF-β1 induced MeT5A cells upon treatment with FSG-containing serum. Western blot and immunofluorescence assays were used to evaluate the expression of proteins related to PF and PI3K/AKT signalling.
resultsPPI network analysis showed that TP53, EGFR, HSP90AA1, AKT1, CCND1, MYC, STAT3, SRC and ESR1 constitute the core network. KEGG analysis found that the PI3K/AKT signalling pathway was significantly enriched. Molecular docking analysis indicated that the main active ingredient from the component–target network can closely integrate with targets in the PI3K/AKT signalling pathway. Proteomics analysis on TGF-β1-treated MeT5A also indicated that the PI3K/AKT signalling pathway was closely correlated with the effect of FSG in intervening PF. Further in vitro experimental validation showed that FSG decreased the protein levels of FN, Col Ⅰ, α-SMA, ITGβ3, PDK1, p-mTOR and p-AKT and reversed the expression of E-cad in TGF-β1-treated MeT5A cells.
conclusionFSG showed therapeutic effects against PF, mainly by inactivating PI3K/AKT signalling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.